CRTAC1: a novel indicator of lung involvement in SSc

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F25%3AN0000022" target="_blank" >RIV/00023728:_____/25:N0000022 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023728:_____/25:N0000004 RIV/00216208:11110/25:10499905

Výsledek na webu

<a href="https://doi.org/10.1093/rheumatology/keaf269" target="_blank" >https://doi.org/10.1093/rheumatology/keaf269</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/rheumatology/keaf269" target="_blank" >10.1093/rheumatology/keaf269</a>

Jazyk výsledku

angličtina

Název v původním jazyce

CRTAC1: a novel indicator of lung involvement in SSc

Popis výsledku v původním jazyce

Interstitial lung disease (ILD) is the most frequent cause of mortality in patients with SSc. Cartilage acidic protein-1 (CRTAC1), secreted by alveolar type-2 epithelial cells, is a potential biomarker of lung health. This study explores CRTAC1's role in SSc, focusing on pulmonary involvement. We collected plasma samples from 76 SSc patients (65 females, limited cutaneous (lc)SSc: 45, diffuse cutaneous (dc)SSc: 31, ILD: 43, all fulfilled the 2013 ACR/EULAR criteria) and 89 healthy individuals (HC, 37 females). Patients were examined and assessed for the European Scleroderma Study Group (ESSG) activity score, modified Rodnan skin score (mRSS), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), diffusing capacity for carbon monoxide (DLCO) and Medsger Disease Severity Scale (DSS). CRTAC1 levels were measured using the CRTAC1 IQ-ELISA (Ray Biotech).  CRTAC1 levels in plasma were lower in SSc patients compared with HC (P < 0.001). CRTAC1 was decreased in SSc patients with ILD compared with SSc patients without ILD (P = 0.027). Linear modelling showed negative association of CRTAC1 with DSS pulmonary involvement (P = 0.016, β = -2.46) and ESSG activity score (P = 0.047, β = -2.022), and a positive association with DLCO (P = 0.065, β = 1.87), FEV1 (P = 0.1, β = 1.622) and FVC (P = 0.072, β = 1.83). CRTAC1 levels were also decreased in SSc patients with gastrointestinal (P = 0.002) and joint (P = 0.006) involvement and pulmonary arterial hypertension (P = 0.05). Systemic levels of CRTAC1 are decreased in SSc patients, especially among those with ILD, reduced lung function and elevated disease activity. Our findings establish CRTAC1 as a promising biomarker for pulmonary involvement in SSc.

Název v anglickém jazyce

CRTAC1: a novel indicator of lung involvement in SSc

Popis výsledku anglicky

Interstitial lung disease (ILD) is the most frequent cause of mortality in patients with SSc. Cartilage acidic protein-1 (CRTAC1), secreted by alveolar type-2 epithelial cells, is a potential biomarker of lung health. This study explores CRTAC1's role in SSc, focusing on pulmonary involvement. We collected plasma samples from 76 SSc patients (65 females, limited cutaneous (lc)SSc: 45, diffuse cutaneous (dc)SSc: 31, ILD: 43, all fulfilled the 2013 ACR/EULAR criteria) and 89 healthy individuals (HC, 37 females). Patients were examined and assessed for the European Scleroderma Study Group (ESSG) activity score, modified Rodnan skin score (mRSS), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), diffusing capacity for carbon monoxide (DLCO) and Medsger Disease Severity Scale (DSS). CRTAC1 levels were measured using the CRTAC1 IQ-ELISA (Ray Biotech).  CRTAC1 levels in plasma were lower in SSc patients compared with HC (P < 0.001). CRTAC1 was decreased in SSc patients with ILD compared with SSc patients without ILD (P = 0.027). Linear modelling showed negative association of CRTAC1 with DSS pulmonary involvement (P = 0.016, β = -2.46) and ESSG activity score (P = 0.047, β = -2.022), and a positive association with DLCO (P = 0.065, β = 1.87), FEV1 (P = 0.1, β = 1.622) and FVC (P = 0.072, β = 1.83). CRTAC1 levels were also decreased in SSc patients with gastrointestinal (P = 0.002) and joint (P = 0.006) involvement and pulmonary arterial hypertension (P = 0.05). Systemic levels of CRTAC1 are decreased in SSc patients, especially among those with ILD, reduced lung function and elevated disease activity. Our findings establish CRTAC1 as a promising biomarker for pulmonary involvement in SSc.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30226 - Rheumatology

Projekt

<a href="/cs/project/LM2023033" target="_blank" >LM2023033: Síť českých biobank</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

RHEUMATOLOGY

ISSN

1462-0324

e-ISSN

1462-0332

Svazek periodika

64

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

4834-4838

Kód UT WoS článku

001503999900001

EID výsledku v databázi Scopus

2-s2.0-105012932153